HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by University of North Carolina, Chapel Hill
University of Florida
Information provided by (Responsible Party):
Michael Fried, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
First received: November 10, 2011
Last updated: April 7, 2016
Last verified: April 2016

November 10, 2011
April 7, 2016
November 2011
December 2016   (final data collection date for primary outcome measure)
Sustained virological response (SVR) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
The primary outcome measure is the occurence (yes or no) of SVR, defined as undetectable HCV RNA in serum at least 3 months after stopping therapy. Point estimates and confidence intervals will be calculated to describe the frequency of SVR in various sub-populations enrolled in HCV-TARGET.
Same as current
Complete list of historical versions of study NCT01474811 on ClinicalTrials.gov Archive Site
  • Treatment persistence [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Treatment persistence will be the duration of treatment measured from the first dose of medication until treatment is discontinued. Reasons for premature discontinuation of treatment will be recorded.
  • Virological breakthrough [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    The occurrence of virological breakthrough defined as an increase of HCV RNA by at least 1-log over nadir or to >100 IU if previously undetectable.
  • Management of adverse events [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Specific interventions to manage selected adverse events, such as anemia and skin rash, will be tabulated and described
Same as current
Not Provided
Not Provided
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
The primary purpose of the HCV-TARGET study is to establish a nationwide registry of patients undergoing treatment with antiviral therapies for chronic hepatitis C (HCV) at both academic and community practices.

HCV-TARGET is a longitudinal, observational study that will create a carefully maintained research registry of HCV patients treated with antiviral therapies designed to rapidly inform strategies for better management of populations underrepresented in clinical trials, identify and remediate educational gaps relative to treatment guidelines and adverse event management in order to optimize rates of sustained virological response (SVR), and serve as the core resource for important collaborative translational studies utilizing biospecimens and clinical data from diverse patient populations.

HCV-TARGET is a cooperative academic consortium of principal investigators from Clinical and Translational Award (CTSA)-funded academic institutions and community-based sites affiliated with the academic sites in geographic proximity. The Clinical Coordinating Center (CCC) resides at the University of Florida and the Data Coordinating Center (DCC) resides at the University of North Carolina at Chapel Hill.

The HCV-TARGET registry will characterize the population of chronic hepatitis C (HCV) patients who are being treated with antiviral therapies at academic and community sites. Patient characteristics such as age, race, ethnicity, comorbidity, and disease and treatment status will be examined.

HCV-TARGET will also:

  1. Provide baseline and treatment response data that will be used to pre-identify candidates for enrollment in future clinical trials. HCV-TARGET will also develop a well-characterized cohort of protease inhibitor treatment failures to be considered for future trials.
  2. Establish and maintain data, a specimen bank and other resources for ancillary studies of the pathogenesis, diagnosis, natural history and treatment of HCV infection.

This study will investigate various aspects of treatment response to regimens containing direct-acting antiviral agents for the treatment of chronic hepatitis C, including the following:

  • Patients underrepresented in clinical trials of approved antiviral therapies(including African-Americans, patients with cirrhosis, and patients that are considered null responders to treatment.)
  • Treatment persistence
  • Virological breakthrough
  • Impact of viral load measurement on treatment efficacy
  • Adverse Event Management and Surveillance.

The secondary aims for this study will investigate the following:

  • Sustained virological response (SVR) rates and safety in special populations.
  • Surveillance of drug-drug interactions.
  • Treatment and management adherence.
  • Pretreatment Education in HCV patient population.
  • Use of specialty pharmacy for hepatitis C therapy.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA

All patients will be invited to participate in the HCV-TARGET Biorepository Specimen Bank (BSB).

The following will be collected: Blood (Serum and DNA).

All samples will be collected on a voluntary basis and participation in this project will not affect participation in the main study.

Samples collected will be stored at the University of Florida for up to 15 years after the end of the study (database closure) at which time they will be destroyed. The implementation and use of the BSB specimens is governed by the University of Florida Biospecimen Repository policy to ensure the appropriate use of the deposited samples.

Non-Probability Sample
Male and female adult patients: Aged 18 and older with chronic HCV treated with triple therapy (including protease inhibitors).
Hepatitis C
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All adult patients (age 18 or older) being treated with antiviral HCV treatment regimens that contain telaprevir or boceprevir.

Exclusion Criteria:

  • Inability to provide written informed consent.
  • Currently participating in another clinical trial of hepatitis C therapeutics. Studies comparing HCV RNA assays are not considered exclusionary.
18 Years and older
United States,   Canada,   Germany,   Puerto Rico
Not Provided
Not Provided
Michael Fried, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
University of Florida
Principal Investigator: Michael W. Fried, M.D. University of North Carolina, Chapel Hill
Principal Investigator: David R. Nelson, M.D. University of Florida
University of North Carolina, Chapel Hill
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP